Fieldview Capital Management LLC Buys Shares of 5,841 Protagonist Therapeutics, Inc. $PTGX

Fieldview Capital Management LLC bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 5,841 shares of the company’s stock, valued at approximately $510,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Kennedy Capital Management LLC grew its stake in Protagonist Therapeutics by 6.2% in the fourth quarter. Kennedy Capital Management LLC now owns 221,444 shares of the company’s stock valued at $19,341,000 after purchasing an additional 13,007 shares in the last quarter. Dymon Asia Capital Singapore PTE. LTD. purchased a new position in Protagonist Therapeutics in the fourth quarter valued at about $873,000. Barclays PLC grew its stake in Protagonist Therapeutics by 9.5% in the fourth quarter. Barclays PLC now owns 187,642 shares of the company’s stock valued at $16,389,000 after purchasing an additional 16,236 shares in the last quarter. FORA Capital LLC grew its stake in Protagonist Therapeutics by 147.8% in the fourth quarter. FORA Capital LLC now owns 9,130 shares of the company’s stock valued at $788,000 after purchasing an additional 5,445 shares in the last quarter. Finally, Quinn Opportunity Partners LLC purchased a new position in Protagonist Therapeutics in the fourth quarter valued at about $4,826,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Buying and Selling

In related news, Director Bryan Giraudo sold 6,000 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $100.00, for a total transaction of $600,000.00. Following the completion of the transaction, the director owned 31,825 shares of the company’s stock, valued at approximately $3,182,500. The trade was a 15.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William D. Waddill sold 9,000 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $107.68, for a total value of $969,120.00. Following the transaction, the director directly owned 7,825 shares of the company’s stock, valued at $842,596. This represents a 53.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 272,345 shares of company stock valued at $27,676,386. 5.19% of the stock is owned by corporate insiders.

Protagonist Therapeutics Price Performance

Shares of NASDAQ:PTGX opened at $112.46 on Tuesday. Protagonist Therapeutics, Inc. has a fifty-two week low of $49.38 and a fifty-two week high of $112.77. The business has a 50-day moving average of $101.89 and a two-hundred day moving average of $93.42. The stock has a market capitalization of $7.23 billion, a P/E ratio of -62.13 and a beta of 1.86.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The company had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $11.70 million. As a group, research analysts expect that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on PTGX. Leerink Partners boosted their target price on Protagonist Therapeutics from $107.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, March 19th. Wolfe Research began coverage on Protagonist Therapeutics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $135.00 target price on the stock. Wedbush boosted their target price on Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. boosted their price target on Protagonist Therapeutics from $95.00 to $106.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. Finally, TD Cowen boosted their price target on Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $115.21.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.